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Abstract
Human coagulation factor Xa (FXa) plays a key role in blood coagulation by activating 
prothrombin to thrombin on “stimulated” platelet membranes in the presence of its cofactor factor 
Va (FVa). Phosphatidylserine (PS) exposure on activated platelet membranes promotes 
prothrombin activation by FXa by allosterically regulating FXa. To identify the structural basis of 
this allosteric regulation, we used fluorescence resonance energy transfer (FRET) to monitor 
changes in FXa length in response 1] to soluble PS (dicaproyl-phosphatidylserine; C6PS), 2] to PS 
membranes, and 3] to FVa in the presence of C6PS and membranes. We incorporated a FRET pair 
with donor (fluorescein) at the active site and acceptor (Alexa fluor 555) at FXa N-terminus near 
the membrane. The results demonstrated that FXa structure changes upon binding of C6PS to two 
sites, a regulatory site (Reg site) at the N-terminus (previously identified as involving the Gla and 
EGFN domains) and a presumptive protein-recognition site in the catalytic domain (Prot site). 
Binding of C6PS to the regulatory site increased the inter-probe distance by ~ 3 Å, while 
saturation of both sites further increased the distance by ~ 6.4 Å. FXa binding to a membrane 
produced a smaller length increase (~1.4 Å), indicating that FXa has a somewhat different 
structure on a membrane than when bound to C6PS in solution. However, when both FVa2 (a FVa 
glycoform) and either C6PS or PS-containing membranes bound to FXa, the overall change in 
length was comparable (~ 5.6–5.8 Å), indicating that C6PS and PS-containing membranes in 
conjunction with FVa2 have comparable regulatory effects on FXa. We conclude that the similar 
functional regulation of FXa by C6PS or membranes in conjunction with FVa2 correlates with 
similar structural regulation. The results demonstrate the usefulness of FRET in analyzing 
structure-function relationships in FXa and in the FXa.FVa2 complex.
Correspondence to: Barry R Lentz.
This paper is dedicated to the memory of William H. (Bill) Kane (1956–2012), a devoted physician, a talented scientist, a fine teacher, 
an excellent colleague, and a dear friend.
Author contributions: BRL and KRS planned the experiments and analyzed the data; KRS carried out the FRET measurements; 
KRS and RM isolated the proteins, while KRS carried out the labeling; WHK and MAQ-A developed and provided the clone for 
efficient expression of FVa2 in large quantities; KRS and BRL prepared the first draft, RM edited it, while BRL was responsible for 
the final draft and for responding to reviews.
NIH Public Access
Author Manuscript
Biochem J. Author manuscript; available in PMC 2014 November 12.
Published in final edited form as:























Factor Xa; Factor Va; prothrombinase complex; fluorescence resonance energy transfer (FRET); 
conformational regulation
Introduction
Prothrombinase complex plays a central role in blood coagulation by producing 
thrombin[1]. In assembling the prothrombinase complex, the enzyme FXa binds to its 
cofactor FVa and substrate prothrombin on activated platelet membranes in the presence of 
Ca2+ ions [2,3]. Appearance of phosphatidylserine (PS) on the surface of activated platelets 
is essential for assembly of fully active prothrombinase complex [4,5]. Extensive studies 
using a soluble form of PS (dicaproyl PS, C6PS) have shown that C6PS binds to single 
regulatory sites in both FXa and in a FVa glycoform [6] (FVa2) to control both activity and 
assembly of a FXa∙FVa2 complex in solution[7–12], as does membrane-located PS[10,13]. 
Because the regulatory sites in both proteins are near the membrane binding regions and far 
from the “action ends” of these proteins (active site of FXa, FXa and binding region of 
FVa), PS is an allosteric regulator of both proteins [10,12]. While models of allostery differ, 
most can be interpreted in terms of a shift in average conformational state of a protein upon 
binding of the regulator. While FXa secondary structure and intrinsic fluorescence are 
altered by C6PS binding [14], still unknown is how the overall shape of FXa is altered by PS 
binding. This issue is particularly relevant because FXa has three flexible regions that join 
its four principle domains. Our hypothesis is that information from binding of PS to the N-
terminus travels from the regulatory site near the membrane-binding domains (Gla and 
EGFn)[12] to the catalytic domain via changes in the flexible regions that connect Gla to 
EGFn, EGFn to EGFc, and EGFc to the catalytic domain. If so, we expect to see measurable 
changes in the shape of the molecule as reported for prothrombin when it interacts with 
membranes containing PS[15].
FXa has two chains and four domains(16). The light chain consists of three domains (Gla-
EGFN-EGFC), which are joined by a disulfide linkage to the heavy chain catalytic domain. 
FXa is produced from its zymogen form (FX) by proteolytic cleavage of a peptide bond 
(Arg194-Ile195 in the chymotrypsin numbering system), resulting in release of an activation 
peptide from the N-terminus of the catalytic domain. A decent molecular model for FXa has 
been proposed based on crystal structures and all atom molecular dynamics simulations [17]. 
This model places the active site roughly 8.3 nm from a plane of Ca2+ ions that are 
presumed to sit at the membrane interface, while the corresponding distance in the inactive 
zymogen is predicted to be 9.5 nm. Two fluorescence resonance transfer experiments report 
the distance between active site-located probes and membrane-located probes [18,19], 
although these estimates differed by more than 2 nm. There are several studies, both FRET-
based [18–20] and computation-based [21], that purport to show a change in FXa structure 
upon binding factor Va. All FRET-based measurements reflect changes in distances between 
the FXa active site and a membrane surface. A change in this distance can result from 
conformational changes or from a change in the orientation of FXa relative to the membrane 
surface. The phosphatidylserine (PS) binding site that regulates FXa conformation and 
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activity [8,9,14] is located in the Gla and EGFN domains [12], although membrane binding 
is widely viewed as mediated by the Gla domain [22]. Thus, it is conceivable that FXa 
orients on the membrane surface so that both the plane of Ca2+ ions within the Gla domain 
and its neighboring EGFN/Gla interface lie close to the plane of the membrane. This would 
require considerable reorientation in the flexible regions of the EGFN and EGFC domains 
relative to the orientation seen in the current model for FXa structure [17]. These 
interpretations can be resolved by placing fluorescent probes at two locations within the FXa 
molecule, as we do in this report. In addition, using a soluble short chain PS molecule 
(dicaproyl PS: C6PS), we ask whether interaction with a PS-containing membrane is 
required to trigger FXa conformational changes or whether occupancy of the PS-specific 
regulatory site on FXa is sufficient. Finally, we ask whether interaction with factor Va 
triggers conformational changes in FXa or simply reorients FXa relative to the membrane 
surface.
In order to answer these questions, we investigated C6PS binding and its effect on the 
structure of FXa by monitoring changes in intramolecular FRET signals. To do so, we 
incorporated an appropriate donor-acceptor fluorophore pair in two regions of FXa separated 
by a distance estimated to be roughly 70–90 Å based on a current structural model of FXa 
structure [17]. We recorded the fluorescence intensity of donor-labeled, acceptor-labeled, 
and donor and acceptor in double-labeled FXa with increasing concentrations of C6PS. We 
then calculated EFRET and inter-probe distance as a function of C6PS concentration. The 
results confirmed the existence of two sites in FXa whose occupancy significantly lengthens 
its structure (~9.4 Å out of 80 Å) upon saturation with C6PS, with the regulatory site being 
near the N-terminus and a second linked binding site near the active site [12]. Significantly, 
addition of FVa after occupancy of the regulatory site further lengthened FXa, but not by the 
same amount as addition of FVa after occupancy of the second site, supporting our previous 
hypothesis that the second site is anomalous and part of recognition site(s) for one or more 
proteins[12]. Also of interest, binding of FXa to a PS-containing membrane produced a 
smaller conformational change than seen with C6PS, indicating that the interaction of the 
Gla domain with the membrane surface also plays a role in modulating FXa structure. 
Overall, our results demonstrate a heretofore unrecognized and complex regulation of FXa 
structure by PS, FVa, and a membrane surface.
Experimental Procedures
Materials
Human Factor Xa, prothrombin, Factor X activator from Russell’s viper venom (RVV-X) 
and Fluorescein-labeled EGR-chloromethylketone (FEGRck) were purchased from 
Haematologic Technologies Inc. (Essex Juction, VT). The chromogenic substrates S2765 
and S2238 were purchased from Chromogenix (Bedford, MA, USA). Recombinant human 
factor Va (FVa2) with a N2181Q mutation [6] was expressed in a BHK cell line kindly 
provided by Dr. Rodney Camire (Children’s Hospital of the University of Pennsylvania). 
The factor V NQ (N2181Q) des B DNA was subcloned into the pED vector obtained from 
Wyeth Laboratories (Collegeville, PA, USA) (the NQ mutation eliminates an N-
glycosylation site at Asn-2181 that is partially glycosylated in vivo, with the un-glycosylated 
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form binding significantly more tightly to FXa in the presence of C6PS[6]. Co-transfection 
of the pED FV with psV2Neo into BHK-M cells was followed by selection with G418, 
resulting in stable transfection of rHFV NQ des B with a typical yield of ~4–10 mcg/mL. 
FVa2 was first concentrated on SP Sepharose, then thrombin-activated and purified over 
Mono S HR 5/5 anion-exchange column as previously described[6], yielding milligram 
quantities of fully active, ~95% pure FVa2 (the form of the protein lacking the 
oligosaccharide at position 2181). The activity of FVa2 was assayed using 25:75 
DOPS:DOPC vesicles or C6PS as previously described[11]. Alexa Fluor 555 carboxylic 
acid, succinimidyl ester was purchased from Invitrogen Molecular Probes. 1,2-dihexanoyl-
sn-glycero-3-phospho-L-serine (sodium salt) (C6PS) and 1,2 dioleoyl - 3sn- 
phosphatidylcholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (sodium salt) 
(DOPS) were purchased from Avanti polar Lipids (Birmingham, AL, USA). PD-10 
desalting and HiTrap QFF columns were purchased from GE Healthcare Life Sciences. All 
other chemicals were ACS reagent grade and solvents were of HPLC grade, purchased from 
Fisher Scientific and Sigma Aldrich.
Methods
Design and Preparation of Single and Double Fluorescent Labeled FXa—To 
examine conformational change associated with C6PS binding, we measured intramolecular 
FRET between a donor-acceptor pair incorporated into FXa. Our hypothesis was that 
flexible regions between the Gla, EGFn, EGFc, and catalytic domains are important in 
transmitting information between the regulatory PS binding site in the Gla-EGFn domains 
and the apparently anomalous C6PS binding site in the catalytic domain[12]. Thus, we 
incorporated one fluorophore at the N-terminus (Gla domain) and another in the catalytic 
domain. We incorporated the donor (fluorescein) in the active site using Fluorescein-EGRck 
and the acceptor (Alexa fluor 555) using succinimidyl ester chemistry to label the N-
terminal primary amine. The efficiency of FRET depends upon optimal spectral overlap 
between donor emission and acceptor absorption and on the distance between fluorophores. 
A wide variety of FRET pairs with appropriate spectral overlap have been identified, but one 
must choose an appropriate pair for the distance to be measured. Thus, we chose the 
Fluorescein-Alexa Fluor 555 pair (Förster distance = R0 = 7 nm) for our study based on their 
spectral properties and the reported distance (89 Å, [17]) between their sites of attachment in 
FXa.
The overall design of labeled FXa species and the paths taken to achieve them are given in 
Scheme 1. We first labeled the N-terminal primary amines of FX by incubating overnight at 
4 °C with a 50-fold molar excess of Alexa555 succinimidyl ester in a buffer consisting of 
0.1 M sodium phosphate, 150 mM NaCl at pH 7.2. Selective labeling of proteins at their N-
termini is routinely accomplished at pH 7.2 using succinimidyl esters. The N-terminal α-
amino group pKa (8.9) is considerably lower than that of the lysine ε-amino group (pKa = 
10.5); thus, at pH 7.2 lysine amines are very rarely in the unprotonated state (probability ~ 
0.1%) and remain unreactive towards succinimidyl esters. Since FXa has only 12 exposed 
lysines [23], the probability of labeling a Lys in a FXa under our conditions would be only ~ 
0.01, too small to significantly influence our interpretation of FRET results. FX consists of 
two peptide chains connected by a disulfide linkage; both N-termini will react with 
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Alexa555 succinimidyl ester, yielding a double-labeled FX. Following labeling, the 
unreacted dye was removed by extensive dialysis at 4 °C. The N-terminal-labeled FX was 
then activated by incubating it with RVV-X (1: 100 RVV/X stoichiometry) at 37 °C for 1 
hour in 50 mM Tris, 150 mM NaCl, 5 mM CaCl2, 0.6 % PEG, pH 7.4. This reaction 
removes the catalytic domain N-terminal activation peptide, leaving FXa with acceptor 
A555 only at the Gla-domain N-terminus. Amidolytic activity during RVV treatment was 
measured using the synthetic substrate S2765, whose absorbance was recorded at 405 nm 
using a tunable microplate reader (Versamax; Molecular Device Corp., Sunnyvale, CA). The 
Gla-labeled FXa was fully active by this measure. N-terminal Alexa fluor 555-labeled FXa 
was purified from RVV and cleaved activation peptide using a Hi-Trap anion exchange 
column mounted on a AKTA FPLC instrument (GE Health Care). N-terminal labeled FXa 
eluted at ~ 0.4–0.45 M NaCl. Purity of the labeled FXa was confirmed by fluoroimaging on 
a Typhoon Trio+ variable mode Imager (GE Health Care) followed by Coomassie staining 
of the SDS PAGE gel.
To prepare double-labeled FXa, we then reacted N-terminal-labeled FXa with FEGRck, 
which attaches fluorescein to the active site via the peptide EGR chemically linked to the 
active site histadine. FXa was incubated with a 10-fold molar excess of FEGRck in 50 mM 
Tris, 150 mM NaCl, 5 mM CaCl2, 0.6 % PEG, pH 7.4 at 24°C for 2.5 hour in the dark. The 
progress of active site labeling was monitored using the synthetic substrate S2765, with 
complete loss of amidolytic activity indicating complete labeling. Unreacted FEGRck was 
removed by extensive dialysis at 4 °C with followed by gel filtration on a PD-10 desalting 
column.
The extent of fluorescence labeling was determined as described by Bock[24]. We used 
molar extinction coefficients of 155,000 M−1 cm−1 at 555 nm for Alexa fluor 555 and 84000 
M−1 cm−1 at 495 nm for fluorescein. In estimating fluorophore concentration, we used 
methods and correction factors of 0.08 for Alexa fluor 555 and of 0.19 for fluorescein (from 
Invitrogen) to correct for the contribution of the dye to 280 nm absorbance. The extent of 
labeling was 0.5 for the N-terminal Alexa acceptor and 0.85 for the active-site-located donor 
fluorescein, whether alone or in FXa already labeled with acceptor. Only acceptor extent of 
labeling (fa) is used to correct FRET efficiency.
Preparation of Phospholipid Vesicles—The concentrations of di-oleoyl-
phosphatidylcholine (DOPC) and di-oleoyl-phosphatidylserine (DOPS) stock solutions in 
chloroform were determined by micro-phosphate assay [25]. The DOPC stock was “spiked” 
with 14C-dipalmitoyl phosphatidylcholine (0.01 mol fraction) and its specific activity 
determined by scintillation counting. Lipid stock solutions were mixed to obtain a stock 
containing 75% DOPC (14C, radiolabeled) and 25% DOPS in chloroform. Appropriate 
volumes of this solution were removed for each experiment and placed in 1 mL amber vials 
from which a stream of nitrogen evaporated the chloroform. Thereafter, the lipid mixture 
was re-dissolved in cyclohexane and a few drops of methanol and then frozen and 
lyophilized to a white powder. To prepare small unilamellar vesicles (SUVs), the 
lyophilized DOPC/DOPS powder was suspended by vigorous vortexing in 2 mL of Tris 
buffer (20 mM Tris, 150 mM NaCl, pH 7.4). The lipid suspension was transferred to an 
annealed glass vial and sonicated using a titanium tip with a Misonix Sonicator 3000. SUVs 
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were isolated via centrifugation at 70,000 rpm at 4 °C for 25 minutes in a Beckman TL-100 
ultracentrifuge. SUV concentration was determined using 14C scintillation counting.
Critical Micelle Concentration Measurements—C6PS CMCs were determined as 
described previously and as is now routine in our lab [11]. No results are presented for C6PS 
concentrations above the measured CMC.
Fluorescence Measurements
Steady state fluorescence and anisotropy measurements were performed in 50 mM Tris, 150 
mM NaCl, 5 mM CaCl2, 0.6% PEG, 7.4 pH upon titration with C6PS at 23°C with a 
FluoroMax-4 spectrofluorometer (Horiba Jobin Yvon Inc., Edison, NJ). Intensity and 
anisotropy were recorded using 4 nm bandwidths for both excitation and emission 
monochromators with excitation at 495 nm for fluorescein and at 551 nm for Alexa 555 and 
emission wavelengths of 520 nm and 565 nm, respectively. The excitation shutter was 
closed except during data collection to limit photo-degradation. Fluorescence experiments 
were performed in 1 mL quartz cuvettes preconditioned with 50 nM unlabeled FXa protein 
in buffer. After the incubation, the cuvette was thrice rinsed with buffer before adding the 
labeled FXa. Anisotropies of labeled FXa were recorded in buffer alone and on addition of 
both C6PS and phospholipid vesicles separately. Fluorescence intensities were recorded 
with increasing concentration of C6PS and the observed fluorescence intensities were 
corrected for dilution. A maximum of 10 µL phospholipid vesicles was added per 
experiment. Measurements were taken ~3 min after each addition, with values averaged to 
obtain a mean and standard deviation. Fluorescence intensities were normalized against the 
intensities of reference samples (aqueous solutions of Alexa Fluor 555 carboxylic acid, 
succinimidyl ester or of FEGRck and were averaged both within and between experiments 
(at least 6 points per value).
Analysis of FRET Data
We calculated FRET efficiency (EFRET) corresponding to each averaged fluorescence 
intensity measurement using equation 1[26]:
(1)
FDA is the fluorescence intensity of donor when acceptor is present in double-labeled FXa, 
and FD is the fluorescence intensity of donor-labeled FXa. The apparent fluorescent 
intensities were corrected using labeling efficiency of the acceptor (fa), i.e., the average 
number of acceptor dye molecules attached per protein (0.5). The distance between the 
donor and acceptor dyes (R) was obtained as:
(2)
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We used 70 Å for the Förster radius (R0) of the fluorescein-Alexa fluor 555 pair, as provided 
by the manufacturer (Invitrogen). FRET efficiency is affected by the distance between 
fluorophores and by the relative orientation of donor and acceptor dipoles, as expressed in 
the orientation factor κ2 [26]. Reported R0 values normally assume κ2 = 2/3, which implies 
random orientation of donor emission and acceptor excitation dipoles. This assumption 
produces “R2/3” from equation 2, namely an estimate of inter-probe distance that depends on 
the assumption that the orientational factor corresponds to random relative orientation. This 
approach is acceptable for estimating changes in R as long as the orientation factor is not 
expected to change significantly with whatever conformational change leads to a change in 
R. To obtain estimates of absolute distances, one must estimate the uncertainty in R 
associated with the uncertainty in κ2. The fluorescence anisotropies of fluorophores in 
single-labeled FXa were recorded using the respective excitation and emission wavelengths 
for fluorescein in donor-labeled FXa and for Alexa fluor 555 in acceptor-labeled FXa. The 
anisotropies of fluorescein and Alexa-labeled FXa were recorded in buffer alone, and then 
under all conditions where EFRET was obtained from experimental intensities. Based on 
theses fluorescence anisotropy measurements and using reported values of the intrinsic 
anisotropies (0.4) (r0) of both dyes[27,28], we calculated relative anisotropies 




Using this range of κ2, we calculated the range of distances between donor and acceptor 
fluorophore covalently attached to amino acid residues of FXa:
(5)
(6)
Because r (thus, κ2) of donor and acceptor varied with increasing C6PS concentration, we 
report a range of values for R and a mean of that range (Table 1). By comparing R2/3 with 
these mean values, we see discrepancies of ~ 2.5 Å. However, the same Table shows that 
changes associated with addition of C6PS generally differed by less than 0.5 Å when 
obtained by these two methods. Therefore, we used R2/3 for C6PS and membrane titrations 
to obtain ΔR in most instances, and calculated ranges of R values in only certain instances to 
estimate what the maximal errors in absolute distances might be.
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Fitting C6PS Titration Data—Because we know that FXa has two C6PS binding sites 
[12,14], we analyzed our titration data according to different models that account for one or 
two binding sites. The data in Figure 2B suggested a model in which two linked sites are 
occupied sequentially. We considered both a single-site binding model and a linked-site, 
sequential binding model.
(7)
Here, Fobs is the observed fluorescence at any C6PS concentration, K1 is the site association 
constant, F0 is the fluorescence intensity in the absence of C6PS (i.e., with the site 
unoccupied), and ΔF is the fluorescence intensity change from occupying this site.
(8)
Again, Fobs is the observed fluorescence at any C6PS concentration, K1 is the site 
association constant for site 1; F0 is the fluorescence intensity in the absence of C6PS; F1 is 
the intensity of the species with site 1 occupied, and F12 is the intensity of the species with 
both sites occupied; and K1 and K12 are the site binding constants for sequential occupancy 
of sites 1 and 2, respectively. We use [C6PS]free ≃ [C6PS]tot = [C6PS] in these expressions 
because the concentration of C6PS is much greater than that of FXa. SigmaPlot (Version 
10.0 for windows, Jandel Scientific) was used for non-linear regression analysis. The 
appropriateness of a fit was judged by the coefficient of determination R2 and F-statistics 
with a P-value test.
Results
Soluble C6PS binding to FXa
We recorded the fluorescence intensity of donor-labeled (FD), acceptor-labeled (FA), and 
donor (FDA) and acceptor (FAD) in double-labeled FXa upon titration with C6PS. Results 
are presented in Figures 1 and 2. The fluorescence intensity of both donor and acceptor 
decreased with increasing C6PS concentration. Addition of buffer alone led to a trivially 
small decrees in intensity due to dilution effects, so the drop in fluorescence intensity was 
due either to quenching by minor impurities in C6PS stocks, but much more likely to 
conformational changes in FXa induced by PS binding. The results for both FA (Figure 1A) 
and FAD (Figure 2A) were consistent with a single-site binding model (Equation S7) with 
saturation at ~200–300 µM C6PS and Kd value 73 ± 8 µM for FA and 67 ± 6 µM for FAD, 
consistent with reports for binding of C6PS mainly to the regulatory site in the Gla-EGFn 
domains[12] with Kd estimated to be 73–90 µM[7,9,14]. It appears that the acceptor probe 
present at the N-terminus is sensitive only to binding to the regulatory site (termed site 
“Reg”), which follows a simple single-site model.
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The fluorescence from the donor fluorescein at the active site behaved differently. The 
curves for FDA (Figure 2B) and FD (Figure 1B) did not fully saturate by 700 µM C6PS, 
above which micelles form. Application of a single-site binding model to these data gave 
333 ± 34 µM for FD and 370 ± 54 µM for FDA (Figures 1B and 2B, dotted curves). The 
residuals for the single-binding-site model were still within error estimates but appeared to 
be non-random, especially for FDA in the range of 0 to 300 µM C6PS (Figure 2B). In this 
case, the curve clearly showed evidence of two events, the first with a tight Kd (~ 56 µM) 
saturating around 200 µM C6PS, and the second with a large Kd showing no sign of 
saturating (Figure 2B). Thus, the donor probe in the catalytic domain reports binding to the 
low affinity site in this domain[14] but appears to be sensitive to binding of C6PS to the 
tight N-terminal regulatory site as well. Previous studies have reported that FXa labeled at 
its active site with a different fluorescent probe (Dansyl; DEGR-Xa) bound C6PS according 
to a two-linked-site, sequential binding model, a conclusion made possible by C6PS 
triggering fluorescence changes of opposite signs upon occupying the two sites [14]. In the 
case of FEGR-Xa, we apparently did not have this lucky situation, so the data were less 
useful in defining all four parameters needed to define the two-linked-site, sequential 
binding model (K1, K12, F1, and F12, Equation 8). Nonetheless, the FDA data indicate that 
binding to the tight site in the regulatory domain triggers changes in the distance between 
the probes in the regulatory and active site regions. Because of this and because the FDA 
data appeared to have a greater indication of two-site binding, we focused first on this data 
set. We initially tried fixing K1 at 73 µM, but variation of K12, F1, and F12 could not 
produce the curvature in the data seen at low C6PS concentration (0–150 µM). We next 
fixed F1 at the apparent plateau in the FDA data from 140–175 µM C6PS (0.804; Figure 2B) 
and fixed F12 based on the first round of χ2 minimization (714 µM), and then varied K1 and 
F12 to obtain Kd1 = 56 µM and F12 = 0.694. This adjustment led to a slightly better fit in the 
low C6PS region but still not significantly better than a single-site model. Next, we allowed 
F12 and K12 to vary with Kd1 = 56 µM and F1 = 0.804 fixed to obtain new estimates of K12 
(Kd12 ≈ 1000µM, F12 = 0.657). This approach improved the fit above 200 µM C6PS without 
significantly degrading it below 175 µM. Finally, we re-optimized K1 with all other 
parameters fixed to obtain Kd1 = 50 ± 12 µM and significantly better residuals than obtained 
with a single-site model over the range of C6PS concentration from 0 to 120 µM (Figure 
2B). The only way to improve the fit between 0 and 120 µM was to allow both K1 and F1 to 
vary and optimize to physically unreasonable values (Kd1 = 15 µM, F1 = 0.813). We 
conclude that, while a sequential, linked-site model offers a slightly better description of the 
FDA data at both low (< 100 µM) and middle range (200–400 µM) C6PS concentrations, 
such a model still provides an incomplete description of the data in the range of 175–250 
µM C6PS. Either there may be more than two sites or the linked, sequential binding model is 
inappropriate. Because the former is proven untrue by equilibrium dialysis experiments [12], 
we conclude that linkage between the weak site (“Prot” site) and the tight site (“Reg” site) is 
likely more complex than we can discern from our data. Our previous analysis of C6PS 
binding to FXa suggested both such linkage, but ultimately required explanation in terms of 
dimer formation via interactions between the catalytic domains of two FXa molecules 
[14,23]. This could be a likely explanation for our imperfect description of FDA.
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Next, we attempted to describe the FD data analytically. Application of the single-site model 
produced the dotted curve in Figure 1B with the residuals shown below the data, with kd = 
333 ± 34 and ΔFsat = 0.20 ± 0.010. As is evident, the residuals from the single-site model 
were within acceptable limits and showed limited persistence except at high C6PS 
concentrations. However, this Kd is not what we obtain from the FDA results for either Kd1 
or Kd12, but is in between these values. Based on these observations, it was clear that the FD 
data alone would not permit estimation of the critical parameters required for describing this 
data set (F1, F12, Kd1 and Kd12). Thus, we asked whether we could reasonably describe the 
FD data by a two-linked-site sequential binding model (Equation 8) using binding constants 
that offered the best description of the FDA data so as to obtain F1 and F12 estimates 
consistent with the analysis of the FDA data. Again, we followed an iterative procedure 
similar to that described for the FDA data to determine whether a sequential, two-linked site 
model might improve the description of the FD data. We first adjusted F12 with Kd1 and 
Kd12 fixed at values based on fitting FDA (53 µM and 714 µM), and F1 (0.946) based on 
visual examination of the data. We next varied both F1 and F12 to obtain new estimates of 
these parameters with K1 and K12 fixed as above. Then, we used a very weak value of Kd12 
as obtained from FDA analysis (1000 µM), and found that only F12 (not the experimentally 
estimated value of F1) was sensitive to the value of Kd12. We next fixed Kd12 at its initial 
value (714 µM) and Kd1 at the value 73 µM reported previously [9] to conclude that the 
optimal F1 was not sensitive to Kd12. With this information, we fixed F1 (0.946), F12 
(0.7697) and optimized Kd1 to obtain 68 µM. This estimate of kd1 was then fixed and K12 
and F12 re-optimized to obtain Kd12 = 769 µM and F12 = 0.758, respectively. Although the 
FD and FDA data contained insufficient information to precisely define the Reg and Prot site 
binding constants (K1 and K12), we showed in this way that analyses of both sets of data 
according to the two-linked-site sequential model were consistent with a fairly tight Reg site 
in the regulatory region (kd1 ~ 56–73 µM) and a weak linked site in the catalytic site region 
(Prot site, kd12 ~ 770 – 1100 µM). These values agree with previous estimates: Kd1 ~ 73 µM 
[9] and Kd1 ~ 90µM with Kd12 ~ 255–1400 µM [14]. We conclude that, while the FD data 
cannot define values of Kd1 and Kd12, the FD data are consistent with binding constants 
estimated from FA, FDA, and FAD curves and with values reported previously [9,14]. This 
result provided the F1 and F12 values from both FDA and FD measurements to calculate 
FRET efficiencies and to estimate changes in inter-probe distances upon binding of C6PS to 
the Reg (F1) or Prot (F12) sites. We address this estimate in the Discussion.
Energy Transfer Efficiency
The efficiency of energy transfer (EFRET) was calculated from experimental FDA and FD 
values using Equation 1 at each C6PS concentration. These efficiencies are plotted against 
C6PS concentration in Figure 3. The biphasic behavior that was obvious in FDA is clearly 
not as evident in EFRET because it is not evident in the FD titration, and EFRET is obtained by 
taking the ratio of FDA over FD (Equation 1). However, there is not the clear, non-random 
distribution of residuals at low C6PS concentration that we saw especially for FDA but to 
some extent for FD. There remains only the peak in residuals at roughly 220 µM that was 
present in both FD and FDA fits in the range of 175–250 µM. Because the abilities of single-
site or two-linked sequential-sites models were barely indistinguishable in describing these 
data, this left uncertainty as to how best to determine EFRET for the two states defined by 
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occupying the two C6PS sites on FXa. We used two procedures. First, we reasoned that 
saturation of the regulatory site (site 1) was likely occurring in the range of C6PS 
concentrations for which residuals were maximal, roughly 175–250 µM for both FDA and 
FD, with at 200 µM C6PS actually used to calculate EFRET,1. A second, and more 
straightforward approach was to use F1 values obtained from fitting the FDA and FD titration 
curves to the sequential, two-site model to obtain EFRET for site 1. The values of ΔR2/3,R 
(the change in inter-probe distance for occupation of the regulatory site) by these two 
methods were −0.057 and −0.052, respectively. We again considered two methods to 
estimate the EFRET (and thus R) associated with occupying the second C6PS site in FXa. 
The first was to simply use FD and FDA for the highest C6PS concentration accessible (700 
µM), above which C6PS forms micelles under our experimental conditions. The ΔRP values 
obtained at 700 µM C6PS were 5.8 Å by the κ2 = 2/3 method versus 5.2 Å by the κ2- range 
method. The second and again most direct method was to use F12 from fitting FDA and FD 
titrations to the sequential, two-component binding model. The final saturation obtained by 
the second method ΔRP was quite large (9Å by the κ2-range method and 9.4Å by the R2/3 
method). Values from different methods are compared in Table 1’s fourth and fifth rows. 
From this, we judge that the second C6PS site is quite weak and is not saturated even at the 
highest C6PS concentrations experimentally accessible.
As noted, uncertainty in κ2 affected our estimates of R. κ2 factors can be estimated from 
relative fluorescence anisotropies of the two probes involved in the FRET pair [29] (see 
Equations 3–6). Fluorescence anisotropies of donor (rD) and acceptor (rA) were recorded for 
FXa in the three states of C6PS occupation considered here: FXa (rD = 0.17; rA = 0.24); 
FXa.C6PS (rD = 0.18; rA = 0.27); and of FXa.(C6PS)2 (rD = 0.22; rA = 0.29). Minimal and 
maximal estimates of R obtained from Equations 4–6 are given in Table 1 along with the 
values obtained using κ2 of 2/3. Comparing R values obtained using κ2 of 2/3 with the mean 
of the range using proper κ2 corrections (Tables 1 & 2), the R values with κ2 of 2/3 were 
always about 2.5 Å smaller than the mean of those obtained using κ2min and κ2max from 
Equations 5 and 6. However, the changes in distances associated with going from state FXa 
to state FXa.C6PS (site Reg occupied) to state FXa.(C6PS)2 (both Reg and Prot site 
occupied) were nearly the same (within 0.5 Å) for both methods of estimating RR and RP. 
The fact that distances calculated with a κ2 of 2/3 were slightly smaller indicates that probe 
dipoles were somewhat favorably oriented in the FXa molecule. The fact that changes in R 
between states were not significantly influenced by the exact value of κ2 means that the 
orientation effect was not significantly different in the different states. Thus, we use R2/3 for 
further interpretations.
Factor Va Binding Replaces C6PS in the Weak or Prot Site
In FXa.(C6PS)2, C6PS occupies the regulatory site (Reg site) in the EGFn-Gla domains and 
the anomalous site in the catalytic domain (Prot-site), which we have previously suggested 
might be a protein-binding site [12]. To test this suggestion, we performed experiments in 
which FVa2 (final concentration 50 nM) was added to FXa (15 nM) following a 3-minute 
incubation with increasing concentrations of C6PS. After an initial incubation with 200 µM 
C6PS to form FXa.C6PS, we added FVa2 and incubated for 3 minutes to assemble the 
C6PS.FVa2.FXa.C6PS complex. Tightly associated FVa and FXa serve as the essential 
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prothrombin-activating complex that assembles on PS-containing platelet membranes. We 
have shown previously that C6PS triggers assembly of this complex in solution [11,30]. 
Human FVa2 binds C6PS to its regulatory domain (C1) with a Kd,app of 4 nM [10], and then 
binds FXa with a Kd of 0.6 nM [11]. Thus, FVa2’s regulatory site will be saturated with the 
C6PS under our experimental conditions. We calculated the EFRET from the intensities of FD 
and FDA before and after addition of FVa2 in the presence of C6PS. The results are 
displayed in Figure 4. We continued this process until we reached the highest C6PS 
concentration for which C6PS does not form micelles under these conditions (700 µM). It is 
clear that FVa2 and C6PS increased the inter-probe distance by ~ 5.8 Å, 3 Å more than the 
2.8 Å resulting from formation of state FXa.C6PS but comparable to that estimated for FXa.
(C6PS)2 at 700 µM C6PS (5.7 Å, Figure 3). These experiments were repeated with a 
different FXa preparation to yield 2.7 Å for FXa.C6PS and 5.6Å for C6PS.FVa2.FXa.C6PS. 
Interestingly, this change was still much less than the ~ 9.4 Å change estimated for 
formation of the fully saturated FXa.(C6PS)2 state (Table 1), making it clear that the 
C6PS.FVa2.FXa.C6PS state is distinct from the FXa.(C6PS)2 state. The fact that the 
C6PS.FVa2.FXa.C6PS state completely supplanted the FXa.(C6PS)2 at all C6PS 
concentrations above 200 µM (compare Figures 3 and 4) indicates that 
C6PS.FVa2.FXa.C6PS competes successfully with FXa.(C6PS)2 and supports our 
hypothesis that weak binding of C6PS is anomalous and involves a protein-binding site.
Membrane-Association of FXa and formation of a membrane-Associated FVa-FXa Complex
We executed FRET experiments with SUVs and FVa2 to study the conformational changes 
on binding of FVa to membrane-associated FXa. We measured FD and FDA of 15 µM singly 
and doubly labeled FXa in Tris buffer (50mM Tris, 150mM NaCl, 5 mM CaCl2, 7.4 pH) in 
the presence of 150 µM unlabeled FXa and in the presence and absence of 50 µM SUVs. 
The reason for the presence of a 10-fold excess of unlabeled FXa was to minimize the 
contribution from inter-molecular FRET between FXa in dimers on the membrane surface, 
where dimerization is fairly extensive at 5 mM Ca2+ [31]. The recorded FD and FDA values 
were used to calculate EFRET and corresponding inter-probe distances (assuming κ2 = 2/3) 
as recorded in Table 2. The results indicate that the donor-acceptor distance increases by 
~1.4 Å when FXa binds to a PS/PC membrane, a smaller distance than the 2.5 – 2.8 Å we 
observed when C6PS bound to FXa (Table 1). This distance increased by another ~ 4.6 Å 
upon binding of FVa2 to membrane-associated FXa, for a total increase relative to FXa in 
solution of 6.0 Å. We also recorded the fluorescence anisotropy of FXa labeled with 
fluorescein in its active site (donor FXa). As seen in Table 2, this anisotropy was unaltered 
by binding of C6PS to form FXa.C6PS or even by binding of FXa to membranes. However, 
binding to FVa2 in the presence of C6PS or membranes produced a significant increase in 
the anisotropy of fluorescein at the FXa active site. This result implies either a significant 
change in the rotational freedom of the probe attached to the active site or a change in the 
orientational freedom of the active site-bound EGR peptide. In either case, our results mean 
that FVa2 binds to and alters the active site region and that this binding is linked to binding 
of C6PS to the regulatory region. Since many studies show that FVa binds to the FXa 
catalytic domain, our results confirm that Prot site is a protein-binding site in the catalytic 
domain that only anomalously responds to C6PS.
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Previous studies have suggested that up-regulation of FXa by C6PS is due to conformational 
changes induced by C6PS binding to two sites, but these reports did not provide direct 
evidence of large-scale changes in structure [7,12]. The acceptor probe (Alexa fluor 555) at 
the N-terminus responded to C6PS titration with a Kd1 (~73 µM), making it clear that it 
monitored binding to the regulatory site previously shown to exist in the Gla-EGFn region 
[12] with a Kd in the range of 60–90 µM [7–9]. Our results reinforce the regulatory site’s 
location and clearly show that FXa extends in length by ~ 2.8 Å (3.6%) upon occupancy of 
this site by C6PS. The uncertainties in our measured distance changes are much smaller 
(~0.7%) than this elongation, which thus constitutes a significant change in overall shape of 
the FXa molecule. We showed previously, using FRET, that FXa’s substrates, prothrombin 
and meizothrombin (the active intermediate of prothrombin activation [3]), experience 
significant increases in length and/or changes in orientation on a membrane surface (+9% 
for meizothrombin and −22% for prothrombin) [15]. While the change in FXa’s length upon 
occupancy of its Reg-site is much less than these changes, it is important to note that 
changes in prothrombin and meizothrombin are much less certain, both because they were 
measured with respect to a membrane-located probe and because the dimensions of the 
proteins in solution were estimated by hydrodynamics and not FRET. Nonetheless, the 
current results reinforce that PS (membrane-located or soluble C6PS) triggers significant 
conformational changes in both FXa and its substrates that are very likely associated with 
the 60-fold increase in kcat [9] or with the shift in reaction path associated with membrane- 
[13] or C6PS- [7] binding to FXa.
The Prot-Site
The change in FXa structure upon saturation of the second C6PS site (Prot-site in the FXa 
catalytic domain [12]) was much greater (increase in donor-acceptor distance of ~6.4 Å or 
8%) than that associated with occupying the Reg site (Tables 1 and 2). However, following 
occupancy of the Reg-site by C6PS, addition of FVa2 produced an additional overall change 
in inter-probe distance (ΔR, ~3 Å or 3.7%, Table 2) that was independent of the amount of 
C6PS added (Figure 4), but was considerably less than the extension produced by occupancy 
of the Prot site by C6PS. These observations suggest three conclusions: 1] the Prot-site is 
indeed a protein recognition site that is anomalously occupied at high C6PS concentration; 
2] FVa2 competes quite successfully with C6PS binding to this site; and 3] FVa binding to 
FXa with the regulatory site occupied (FXa.C6PS exists at 200 µM C6PS) elicits a 
substantial additional elongation (3 Å or 3.7%) in FXa beyond that associated with C6PS 
binding to the Reg-site. A significantly larger increase in ΔR occurs when FVa2 is added to 
FXa on a membrane (~ 4.6 Å or 5.8%, Table 2). Finally, we note that the change in inter-
probe distance (ΔR) is greater for saturation of both sites by C6PS (~9.4 Å, Tables 1) than it 
is for saturation of the R site by C6PS followed by FVa2 binding (~5.8 Å, Table 2). The 
implications of these observations are discussed next.
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Mechanistic Implications of Membrane-induced versus C6PS-induced Changes in the 
Presence and Absence of FVa2
The kinetics of activation of prothrombin to its activation intermediates and then their 
further activation to thrombin are quite similar whether PS-containing membranes or C6PS 
are used to activate FXa [7,11]. Thus, we presumed that FXa would undergo similar 
structural changes upon binding to C6PS in solution as it does upon binding to PS-
containing membranes. We found this presumption to be only qualitatively true (ΔR ~ 1.4 Å 
for PS-containing membranes versus ~ 2.8 Å with C6PS; Tables 1 and 2). We suggest that 
this has to do with active-site-labeled FXa dimer formation on a membrane that does not 
occur when C6PS binds to FXa in solution [23,31]. Thus, our hypothesis is that FXa 
dimerization limits extension of FXa on a PS-containing membrane, but that FVa2 binding 
to the catalytic domain competes with dimerization and extends the FXa molecule. This is 
consistent with the report that FXa dimerization competes with FVa2 binding in solution 
[32] and with the observation that elongation caused by FVa2 binding to FXa on a 
membrane is greater than observed for FXa whose Reg-site is occupied by C6PS. However, 
the membrane-assembled prothrombinase complex did show comparable FXa elongation 
when assembled by C6PS in solution (~ 5.8 Å) and when assembled on PS-containing 
membranes (ΔR ~ 5.6 Å, Table 2). This is consistent with the report that C6PS and 
membranes in conjunction with FVa2 elicit nearly identical functional changes [11,30]. It 
seems that, while C6PS and membranes may not act identically in regulating FXa structure 
and activity, in the presence of FVa2, they have similar effects. However additional FRET 
distances and more complete structural studies are required to further test this hypothesis.
It is well known that prothrombin activation can occur via two intermediates, MzIIa (cleave 
at R320) or Pre2 (cleave at R271), or can occur without the release of an intermediate 
(channeling) [33–35]. Activation via MzIIa has generally been reported in the presence of 
synthetic PS-containing membranes. It is recently reported that prothrombin activation 
proceeds via Pre2 rather than MzIIa in the presence of platelet preparations [36]. Based on 
these observations, it is tempting to speculate that the conformations of enzyme, cofactor, or 
substrate on these different membranes might be different. Both FVa and PS-containing 
model membranes promote the channeling activation pathway, although the extent to which 
they do depends on experimental conditions (membrane, FVa, FXa concentrations) [35]. 
FVa is most critical to promoting the chanelling mechanism over a broad range of 
membranes conditions [35] and promotes chanelling even in the absence of membranes [37]. 
Beause experimental conditions are important in promotion channeling versus MzIIa 
release, we can not compare results obtained under very different experimental conditions to 
conclude that FXa assumes different conformations on platrelet-derived versus model 
membranes. However, our results make clear that binding to FVa, both on a membrane and 
in solution, produces substantial and similar conformational changes in FXa, making it 
likely that the influence of FVa on prothrombin activation pathway is related to these 
conformational changes.
Comparison to Literature
In solution, we estimate the length of FXa to be ~ 78 – 81 Å from the active site fluorescein 
acceptor to the N-terminal Alexa fluor 555 donor (Tables 1 and 2). The most reliable 
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atomistic model we have [17] estimates the distance between the active site Ser and the N-
terminus to be 83 Å. We do not wish to over interpret this agreement, but we take it mean 
that the atomistic model of Venkateswarlu et al. provides a reasonable reference point for 
thinking about FXa in solution.
A previous FRET study reported that that the distance from a dansyl probe linked to the 
active-site blocking peptide EGR a PS-containing membrane surface was 61 Å and 
increased by ~ 8 Å upon binding of FVa to FXa [18]. However, another paper from these 
researchers used a fluorescein attached to the active-site blocking peptide FPR and found 
this to be 84 Å from a membrane-located probe [19]. This group attributed this difference to 
different orientations of the EGR and FPR peptides in the active site [19], although it could 
also reflect the different sizes and electronic structures of the dansyl and fluorescein probes. 
Another paper reported that the distance from fluorescein attached to the FPR peptide to a 
membrane-located probe increased from 72 Å to 75 Å upon binding of FVa [20]. Our results 
show that FXa elongates by 4.6 Å from 79 Å upon binding FVa2 on a membrane. However, 
we used fluorescein attached to the EGR peptide and measure the distance from the active 
site to a location that, based on our current understanding of Gla domain binding to PS-
containing membranes [22], should be at the Ca2+ plane in the lipid phosphate plane, or at 
least 5–8 Å below the level of head-group-bound fluorescent probes. Based on this, our 
results compare best with measurements made with fluorescein attached to the FPR peptide 
[20]. However, it remains unclear whether FRET distances obtained with membrane-located 
probes [18–20] reflect the length the FXa molecule or the orientation of FXa on the 
membrane, or both. We removed this ambiguity by placing probes in two positions in FXa. 
We can thus conclude that FXa elongates slightly (~ 2.8 Å) relative to the best atomistic 
model [17] upon binding C6PS to it regulatory site. Based on locating a Lys in the FXa 
dimer interface, it has been argued that FXa in a membrane-assocaited dimer may not be 
well represented by the atomistic model [17] with the Ca2+ plane located at the membrane 
phosphate plane [23]. Our results support this suggestion in that the FRET distance we 
measure is slightly shorter in a membrane-associated dimer that in C6PS-bound FXa in 
solution (Tables 1 and 2).
While there is little quantitative agreement between the three published works that report 
FRET distances between active-site- and membrane-located probes, two agree that this 
distance increases upon binding of FVa. One study puts the change in active-site-to-
membrane distance as being somewhat smaller (~ 4% [20]) and one much larger (~13% 
[18]) than the change in FXa length (~ 6%) that we unambiguously record for binding of 
FXa to FVa2 in solution or on a PS-containing membrane (Tables 1 and 2). Given the 
difficulties noted in comparing published estimates of the membrane-to-active-site distance, 
there is ambiguity in trying to compare any one published result to our results. If we accept 
the measuremnts of Qureshi et al. as being in closet agreement with ours, we would 
conclude that FXa alters very little its alignment with the membrane surface upon binding 
membrane-assocaited FVa. However, if we accept the measurments of Huston et al., we 
would conclude that FXa binds to a PS-containing membrane at a substantial angle to the 
membrane surface but “straightens up” upon binding to FVa2. Additional work is required to 
resolve this ambiguity.
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Recently, a crystal structure of a snake venom protein (P textilis propseutarin C) analogous 
to the FXa-FVa complex has appeared [38]. One might think that this would offer the 
perfect comparison to our measuements. However, the construct that was crystalized lacks 
the EGFn and Gla domains of whole FXa. It is thus impossible to glean from this structure a 
direct comparison to our measurents.
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EFRET efficiency of energy transfer
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(A) Fluorescence intensity of acceptor-labeled FXa (15 nM) in Tris buffer (50 mM Tris, 150 
mM NaCl, 5 mM CaCl2, 0.6% PEG, 7.4 pH) upon titration with C6PS at 23°C. Observed 
intensities were normalized against the intensity of an Alexa fluor 555 reference solution. 
Symbols represent an average value with standard deviations as error bars. The dotted curve 
drawn through the symbols show a fit of the data to a single-site binding model which gives 
kd1=73 µM. (B) Fluorescence intensity of donor labeled FXa (15 nM) upon titration with 
C6PS at 23°C. Observed intensities were normalized against the intensity of a fluorescein 
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reference solution. Symbols and error bars are as in Frame A, as is the dotted curve that 
shows a fit of the data to a single-site binding model with kd1=333 µM. The solid curve 
drawn through the symbols shows a fit to a sequential-linked-site model wherein we fixed 
the first binding site kd1 at 73 µM, resulting in the second binding site constant kd2 being 
714 µM. The frames below frames A and B show the residuals for each predicted curve 
compared to experimental values.
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(A) Normalized fluorescence intensity of acceptor in double labeled FXa (15 nM) upon 
titration with C6PS at 23°C, with details as described in Figure 1. Again, the dotted curve 
shows a fit of the data to a single-site binding model with kd1=76 µM. (B) Normalized 
fluorescence of donor in double labeled FXa (15 nM) upon titration with C6PS at 23°C. As 
in Figure 1, the dotted curve shows a fit of the data to a single-site binding model with 
kd1=370 µM, while the solid curve shows a fit with a sequential-linked-site model with the 
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first binding site constant kd1=50 µM and an adjusted second binding site constant kd1=1000 
µM. Residual plots are shown below each frame.
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Variation of FRET efficiency with C6PS concentration obtained from the data in Figures 2B 
and 3B using Equation 1 in Material and Methods.
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FRET efficiency as a function of C6PS binding in the presence of FVa2. FRET efficiency 
values were calculated from fluorescence intensity data of FD and FD(A) using equation 1 
mentioned in Materials and Methods. Average FRET efficiency values on each addition of 
either C6PS or FVa2 are presented as symbols along with their standard deviations as error 
bars. FRET efficiency of FXa (in 1:9 ratio of labeled: unlabeled FXa) (circle), followed by 
addition of 200 µM C6PS (downward triangle), followed by addition of FVa2 (square), then 
increases in total C6PS to 400 µM (diamond) and to 700 µM (upward triangle).
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Schematic representation of preparation of fluorophore-labeled FXa. FX was first labeled 
with donor (Alexa Fluor 555 succinimidyl ester; A555-NHS) followed by activation to 
remove the activation peptide at its N-terminus. The acceptor (fluorescein-labeled EGR-
chloromethylketone; FEGRck) was then added to the active site of A555-Xa to produce 
doubly labeled peptide or to FXa to produce singly labeled peptide.
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Table 2
The observed anisotropy values of fluorescein (donor), calculated FRET efficiency (Efret) values and 
corresponding calculated distances between covalently attached fluorophores assuming random dipolar 
orientation (κ2=2/3). FRET efficiency values for each addition of SUV, C6PS and FVa were calculated from 
fluorescence intensity data of FD and FD(A) using equation 1 mentioned in Materials and Methods. The error 
value of Efret was calculated from the sum of fractional error of observed FD and FDA.
Anisotropy Efret Distance (Å)
FXa 0.17 ± 0.003 0.344 ± 0.003 77.9 ± 0.26
FXa-Membrane 0.17 ± 0.002 0.320 ± 0.004 79.3 ± 0.34
FXa-Membrane-FVa 0.22 ± 0.003 0.277 ± 0.004 83.9 ± 0.33
FXa 0.17 ± 0.003 0.340 ± 0.004 78.1 ± 0.34
FXa-200µMC6PS 0.18 ± 0.005 0.295 ± 0.003 80.9 ± 0.35
FXa-200µMC6PS-FVa 0.21 ± 0.003 0.251 ± 0.003 83.9 ± 0.34
FXa-400µMC6PS-FVa 0.22 ± 0.002 0.254 ± 0.003 83.8 ± 0.27
FXa-700µMC6PS-FVa 0.22 ± 0.002 0.252 ± 0.003 83.9 ± 0.31
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